Newsletter Subject

Always pay attention to relative strength

From

bullseyeoptiontrading.com

Email Address

jeffs-bullseye@b.bullseyeoptiontrading.com

Sent On

Thu, Sep 7, 2023 05:38 PM

Email Preheader Text

When the markets are falling, look for GREEN stocks…

When the markets are falling, look for GREEN stocks…                                                                                                                                                                                                                                                                                                                                                                                                                 September 07, 2023 *Sponsored by Sica Media I had a feeling we were in for some rocky weather then the market started to roll over yesterday. I think the bumpy ride is almost over though (for a while). Maybe we will see a little dip at the open tomorrow for the market, but I am building a “wishlist” of trades I am looking for. Mainly larger stocks that I will use options on, like NVAX, META, and I even think NVDA is a great target right now. But, looking at small stocks that also have big potential is another way I like to trade. Those tiny stocks can have “option-like moves” without ever having to pay a high commission for trading, in fact, most brokers now let you trade stocks for free (what a world we live in!) Top of my list into the weekend is the exact same stock I told you about this morning – Citius Pharma (CTXR). This stock is just loaded with potential right now, and I love how it is just now starting to turn the corner. Today, the stock is up a little, while the overall market is a sea of red. That is one of the top ways that I identify strength in a stock – how does it perform when the market is down? This is called “relative strength,” and it is something that most pro traders will always keep an eye on. When you find a stock that is green on down market day, you better pay attention because something big might be coming! I definitely think you should keep CTXR on the top of your “small stock radar” as we head into Friday. There is a lot going on with this one. I outlined several of my top reasons to look at it right now in the highlights below – pay attention to part about what the analysts who cover this stock think! Have a great trading day. Stay safe, and I will be back tomorrow with more updates. ______________________________________________________________________ Hey folks, Jeff Bishop here, and I have to say: I love stocks that are hovering around a dollar. They’re my bread and butter when I’m looking for big upward moves on non-options plays. There’s just something magic about that price range… Magic… or is it? It’s not just because I can buy a lot of shares for the price of a nice dinner. If you’ve spent any time watching and researching Nasdaq-listed stocks at that valuation, you know that if they drop below the $1.00 mark for 30 consecutive business days, they are put on notice that they risk being delisted, which is a major blow to a company. REREAD THAT 👆 , IT’S IMPORTANT INFO FOR TRADERS. If you didn’t know it, you can read all about that [here](. It’s an interesting thing most people don’t know about unless they are hardcore small-stock trader like I am. Most companies will naturally pull out all the stops to prevent this from happening. Company insiders are likely to cling to their shares and new share issuances are unlikely. The upshot for profit-seekers is a great, low-price buying opportunity with something of a floor of resistance. Of course, savvy investors must exercise due diligence and ensure the company is fundamentally sound… With that in mind, today’s Bright Idea 💡 is a company that should definitely be on your radar 📡: Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) I brought this late-stage pharmaceutical company to your attention back in early March when I said it was in a very tight “bull flag” formation that could lead to a big move… Sure enough, after a brief wind-up, it rattled off a 58% gain in just five weeks (not bad, huh?). The stock price has pulled back since then, but I’ve kept it on my watchlist since it’s around that special $1.00 mark. Looking at the chart yesterday, I noticed this trend: As you can see, so far this year, every time CTXR has based at a new level, it makes a bounce (sometimes those have been nearly triple-digit bounces!) If that level is below $1.00, the percentage move has been even bigger too.. Well, have a look at where CTXR is basing right now! The past doesn’t guarantee the future, of course, but it can be suggestive. A deeper dive into CTXR gives more reasons for optimism… For starters, I found an [article]( about the company from three days ago. In it, we learn that the company has been shrinking the gap between loss and breakeven, and that three industry analysts covering the company are projecting its final loss in 2024 before – get this – a whopping $45 million in profits in 2025 💰(analyst estimates). At a current market cap of around $135 million (according to [Yahoo!](), that’s a dramatic projection for earnings per share (EPS). Another critical factor to look at when evaluating these small pharma companies is what their cash burn 🔥 looks like relative to their reserves. According to [this August 14 press release](, the company had $33.3 million in cash and cash equivalents as of June 30, and it had extended its “cash runway” to August 2024. That means its runway extends to where analysts project its revenue will pick up… a very good sign. Source: [MarketWatch]( And as the article mentioned above notes: This is especially good news in our era of high interest rates; it means the company is spending its money on salaries and research and not on loans and interest. In addition, while the company has a diverse pipeline of developing therapies, its most promising one, Mino-Lok® — an antibiotic treatment to salvage catheters in patients with catheter-related bloodstream infections — [reached]( the critical 92-event milestone of its Phase 3 trial last month. This heralds the successful end of the Phase 3 trial pending confirmation from independent reviewers. For those unfamiliar with clinical trial phases, a successful Phase 3 trial [generally means FDA approval](… and for CTXR, that means revenue. All of this bodes well for the technical pattern I see lining up… If you’re going to take a big leap, it helps to have a firm footing, and CTXR has just established that beneath the $1.00 line. I won’t be surprised if it takes off in the next few days. I think this is a great idea that merits your attention, and I’ve given you my impressions. But please… as always, do your own homework, and make sure you have a game plan in place that makes sense for you before you ever trade anything. You can start by checking out CTXR’s website [here](. You’ll see an entire “Investors” menu tab that has great resources. In the meantime, happy trading! Let’s hope for a nice bounce in the markets today…  To Your Success, P.S. If you’re new (or just haven’t done it yet), make sure you join our exclusive SMS list. 📲 All you need to do is text the word “RAGE” to (888) 404-5747 to get all of my latest HOT STOCK ideas and access to live trading events! *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. DISCLAIMER Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull STANDARD DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull.com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. Update your email preferences or unsubscribe [here]( © Bullseye Trades 62 Calef Hwy. #233 Lee, NH 03861, United States

EDM Keywords (210)

yesterday yahoo world wishlist whole well weekend website verified variety valuation upshot unsubscribe unlikely unless unfamiliar typical turn trend trading trades traders trade tracked top told though think text testimonials terms takes take surprised suit suggestive stops stock starting starters start spent spending speculative something solicitation shrinking shares services see securities sea say sales salaries said roll risks risk right revenue result resistance research representations relief registered red reasons read rattled put projecting profits price prevent possibly please place pick perform people pay patients past part paid owners optimism one noticed notice notes next new need necessary money merits means maybe may markets market making makes love lot loss looking look loans loaded live little list likely like licensed level let learn know kept join issuer interpret interest instituted indirectly impressions hope homework highlights heralds helps head guarantee green going given get gap future friday free found floor find feeling far factors fact eye extended exact event evaluating established era entitled ensure enforce employees educational drop done dollar disbursements delisted definitely days ctxr cover course consult construed concerns company companies communication coming cling checking cash carries buy butter business building brought brokers breakeven bread beneath believed based attention article around analysts amount always also almost affiliates advertisers addition action access 2024

Marketing emails from bullseyeoptiontrading.com

View More
Sent On

07/12/2024

Sent On

07/12/2024

Sent On

06/12/2024

Sent On

05/12/2024

Sent On

04/12/2024

Sent On

03/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.